Suppr超能文献

永久性左束支起搏的初步经验、可行性及安全性:一项前瞻性单中心研究的结果

Initial experience, feasibility and safety of permanent left bundle branch pacing: results from a prospective single-centre study.

作者信息

Rademakers L M, van den Broek J L P M, Op 't Hof M, Bracke F A

机构信息

Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.

出版信息

Neth Heart J. 2022 May;30(5):258-266. doi: 10.1007/s12471-021-01648-6. Epub 2021 Nov 26.

Abstract

BACKGROUND

Left bundle branch (LBB) pacing is a novel pacing technique which may serve as an alternative to both right ventricular pacing for symptomatic bradycardia and cardiac resynchronisation therapy (CRT). A substantial amount of data is reported by relatively few, highly experienced centres. This study describes the first experience of LBB pacing in a high-volume device centre.

METHODS

Success rates (i.e. the ability to achieve LBB pacing), electrophysiological parameters and complications at implant and up to 6 months of follow-up were prospectively assessed in 100 consecutive patients referred for various pacing indications.

RESULTS

The mean age was 71 ± 11 years and 65% were male. Primary pacing indication was atrioventricular (AV) block in 40%, CRT in 42%, and sinus node dysfunction or refractory atrial fibrillation prior to AV node ablation in 9% each. Baseline left ventricular ejection fraction was < 50% in 57% of patients, mean baseline QRS duration 145 ± 34 ms. Overall LBB pacing was successful in 83 of 100 (83%) patients but tended to be lower in patients with CRT pacing indication (69%, p = ns). Mean left ventricular activation time (LVAT) during LBB pacing was 81 ms and paced QRS duration was 120 ± 19 ms. LBB capture threshold and R‑wave sense at implant was 0.74 ± 0.4 mV at 0.4 ms and 11.9 ± 5.9 V and remained stable at 6‑month follow-up. No complications occurred during implant or follow-up.

CONCLUSION

LBB pacing for bradycardia pacing and resynchronisation therapy can be easily adopted by experienced implanters, with favourable success rates and safety profile.

摘要

背景

左束支起搏是一种新型起搏技术,对于有症状的心动过缓,它可以作为右心室起搏以及心脏再同步治疗(CRT)的替代方法。相对较少的经验丰富的中心报告了大量数据。本研究描述了大容量设备中心首次开展左束支起搏的经验。

方法

前瞻性评估了100例因各种起搏指征转诊的连续患者在植入时以及随访至6个月时的成功率(即实现左束支起搏的能力)、电生理参数和并发症。

结果

平均年龄为71±11岁,65%为男性。主要起搏指征为房室传导阻滞占40%,心脏再同步治疗占42%,窦房结功能障碍或房室结消融术前难治性心房颤动各占9%。57%的患者基线左心室射血分数<50%,平均基线QRS时限为145±34毫秒。100例患者中有83例(83%)成功实现左束支起搏,但有心脏再同步治疗起搏指征的患者成功率较低(69%,p=无统计学意义)。左束支起搏期间的平均左心室激动时间(LVAT)为81毫秒,起搏QRS时限为120±19毫秒。植入时左束支起搏的捕获阈值和R波感知分别为0.74±0.4毫伏(脉宽0.4毫秒)和11.9±5.9伏,在6个月随访时保持稳定。植入或随访期间未发生并发症。

结论

经验丰富的植入者可以轻松采用左束支起搏进行心动过缓起搏和再同步治疗,成功率高且安全性良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dec2/9043049/7742e2a59f22/12471_2021_1648_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验